CVS Health Corporation (NYSE:CVS - Free Report) - Equities research analysts at Leerink Partnrs increased their FY2025 EPS estimates for shares of CVS Health in a report released on Thursday, July 10th. Leerink Partnrs analyst M. Cherny now forecasts that the pharmacy operator will post earnings of $6.18 per share for the year, up from their previous estimate of $6.16. The consensus estimate for CVS Health's current full-year earnings is $5.89 per share.
Several other research firms also recently weighed in on CVS. Cowen reiterated a "buy" rating on shares of CVS Health in a report on Monday, May 5th. Truist Financial lifted their target price on shares of CVS Health from $82.00 to $84.00 and gave the company a "buy" rating in a report on Monday, May 12th. Jefferies Financial Group lifted their target price on shares of CVS Health from $74.00 to $80.00 and gave the company a "buy" rating in a report on Monday, June 30th. Mizuho lifted their target price on shares of CVS Health from $70.00 to $76.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. Finally, Royal Bank Of Canada lifted their target price on shares of CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a report on Monday, May 5th. Two analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, CVS Health presently has an average rating of "Moderate Buy" and an average target price of $75.06.
Check Out Our Latest Report on CVS
CVS Health Stock Down 1.6%
CVS Health stock opened at $65.58 on Friday. CVS Health has a fifty-two week low of $43.56 and a fifty-two week high of $72.51. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.82. The firm has a 50 day moving average price of $65.10 and a 200 day moving average price of $62.08. The company has a market capitalization of $82.96 billion, a PE ratio of 15.65, a price-to-earnings-growth ratio of 0.95 and a beta of 0.57.
CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating the consensus estimate of $1.62 by $0.63. The firm had revenue of $94.59 billion for the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a net margin of 1.39% and a return on equity of 10.59%. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.31 EPS.
Hedge Funds Weigh In On CVS Health
A number of institutional investors and hedge funds have recently modified their holdings of CVS. Kingstone Capital Partners Texas LLC purchased a new stake in CVS Health in the second quarter valued at $155,185,000. IFM Investors Pty Ltd lifted its position in CVS Health by 4.6% in the second quarter. IFM Investors Pty Ltd now owns 238,547 shares of the pharmacy operator's stock valued at $16,455,000 after acquiring an additional 10,457 shares during the last quarter. Grove Bank & Trust lifted its position in CVS Health by 30.2% in the second quarter. Grove Bank & Trust now owns 2,162 shares of the pharmacy operator's stock valued at $149,000 after acquiring an additional 502 shares during the last quarter. Canoe Financial LP lifted its position in CVS Health by 16.1% in the second quarter. Canoe Financial LP now owns 1,612,178 shares of the pharmacy operator's stock valued at $111,208,000 after acquiring an additional 223,983 shares during the last quarter. Finally, Baker Tilly Wealth Management LLC lifted its position in CVS Health by 3.6% in the second quarter. Baker Tilly Wealth Management LLC now owns 13,568 shares of the pharmacy operator's stock valued at $936,000 after acquiring an additional 471 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company's stock.
Insider Activity at CVS Health
In other news, Director Guy P. Sansone bought 1,570 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was purchased at an average price of $63.70 per share, for a total transaction of $100,009.00. Following the completion of the purchase, the director owned 12,007 shares in the company, valued at approximately $764,845.90. This trade represents a 15.04% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.22% of the company's stock.
CVS Health Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Tuesday, July 22nd will be paid a dividend of $0.665 per share. The ex-dividend date of this dividend is Tuesday, July 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.06%. CVS Health's payout ratio is currently 63.48%.
About CVS Health
(
Get Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.